HC Wainwright & Co. Maintains Buy on Annovis Bio, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Annovis Bio (NYSE:ANVS) but reduced the price target from $40 to $30.
November 13, 2023 | 4:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Annovis Bio but decreased the price target from $40 to $30, indicating a potential downside compared to the previous target.
The reduction in price target by HC Wainwright & Co. suggests that they see less upside potential for Annovis Bio's stock price in the short term, which could lead to negative sentiment among investors and a possible decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100